版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
DeptofCriticalCareMedicinePekingUnionMedicalCollegeHospitalICU-acquiredInfectionandStrategyofAntibioticTherapyCostofHospitalStayAssociatedwithResistanceNosocomialInfectioninICUanoverallriskof18%ofacquiringaninfectionduringICUstayoneofthemostcommoncausesofdeathinICUsEPICDataatotalof45%ofpatientshadaninfectionICU-acquiredinfection 21%community-acquiredinfection 14%hospital-acquiredinfectionotherthanICU 10%NosocomialInfection
Vincentetal.JAMA1995;374:639-644(EPIC)NosocomialInfectioninICUPredisposingriskfactorsprolonglengthofICUstayantibioticusagemechanicalventilationurinarycatheterizationpulmonaryarterycatheterizationcentralvenousaccessstressulcerprophylaxisuseofsteroidnutritionalstatusNosocomialInfectioninICUUseofAntibiotics--EPICdataof10,038patients,62%receivedantibioticsforeitherprophylaxisortreatmentNosocomialInfectioninICUPreviousexposuretoantibioticsmodifyintestinalflora,leadingtocolonizationwithresistantbacteria3rdgenerationcephalosporinsfluoroquinolonesvancomycinfavortheselectionofinduciblebeta-lactamaseproducingGNB,suchasPseudomonoasaeruginosa,Enterobacterclocae,Serratiaspp.,andCitrobacterfreundiiNosocomialInfectioninICUCommonpathogenscommunity-acquiredinfectionandearly(<4d)hospital-acquiredinfectionsStreptococcuspneumoniaeHaemophilusinfluenzaeEnterobacteriaceae(Escherichiacoli,Proteusspp.,Klebsiellapneumoniae)MSSAStreptococcianaerobesEPICDatamostcommonpathogensS.aureus 30%P.aeruginosa 29%Coagulase-negativestaphylococci 19%E.coli 13%Enterococcusspp. 12%EmergingPathogensMechanismofResistancetoBeta-lactamAntibioticsDepartmentofCriticalCareMedicinePekingUnionMedicalCollegeHospitalPrincipleofbeta-lactamactionarigidbacterialcellwallprotectsbacteriafrommechanicalandosmoticinsultbeta-lactaminhibitsPBPspreventingformationofthepeptidebridgesproducingweakenedwallactivatingcellwalldegradingenzymes--autolysinbeta-lactaminterfereswithnormalcellwallbiosynthesis,causingimpairedcellularfunction,alteredcellmorphologyorlysisDoesbeta-lactamaseconferresistance?TheamountofenzymeproductsitsabilitytohydrolysetheantibioticinquestionitsinterplaywiththecellularpermeabilitybarriersInducibleBeta-lactamasealsocalledclassIbeta-lactamaseorconstitutivebeta-lactamaseorAmpCbeta-lactamasemostarechromosome-mediatedmajorproducersPseudomonasaeruginosaEnterobactersp.Citrobactersp.Serratiasp.MorganellamorganniiInducibleBeta-lactamasetransientelevationinbeta-lactamasesynthesiswhenabeta-lactamispresentenzymeproductionreturnstoalowlevelwhentheinducerisremovedlowlevelinsufficienttoprotectbacteriaevenagainstdrugsrapidlyhydrolysedbytheenzymesenzymehyperproducer=mutantsthatproduceClassIenzymescontinuouslyatahighlevelActivityofDrugsAgainstOrganismswithElevatedBeta-LactamaseLevelsDecreasedActivityMonobactamsSecond-,Third-generationcephalosporinsBroad-spectrumpenicillinsMaintainActivityImipenem,MeropenemFourth-generationcephalosporinsCiprofloxacin,ofloxacin,etcSMZ/TMPco(exceptP.Aeruginosa)AminoglycosidesAntibiogramofEnterobacterMultiresistantEnterobacterEmergenceofResistancetoCephalosporin,Aminoglycoside,andOtherBeta-LactamTherapy*Cefotaxime,ceftazidime,ceftriaxone,ceftizoxime**Gentamicin,tobramicin,amikacin,netilmicin***Imipenem,piperacillin,ticarcillin,aztreonam,mezlocillin,ticarcillin-clavulanateMultiresistantEnterobacterFactorsAssociatedwithMortalityinPatientswithEnterobacterBacteremiaExtendedspectrumbeta-lactamaseMostareplasmidmediated1to4aminoacidchangesfrombroad-spectrumbeta-lactamases,thereforegreatlyextendingsubstraterangeMajorproducersE.Coli(TEM)Klebsiellasp.(SHV)inhibitedbybeta-lactamaseinhibitorsReliable(relatively)agentsforESBL-producingpathogensCarbapenemsAmikacinCephamycins(exceptMIR-1type;30%ofstrains)Beta-lactamaseinhibitors pip/tazo 30%RinChicago1996 26%RinICU,PUMCH1999AntibiogramofE.coliAntibiogramofKlebsiellaPrevalenceofCAZ-RKlebsiellaFromItokazuG,etal.NationwideStudyofMultiresistanceAmongGram-NegativeBacillifromICUpatientsClinicalInfectiousDiseases1996;23:779-85Cross-Resistancein
CAZ-RKlebsiellaFromItokazuG,etal.NationwideStudyofMultiresistanceAmongGram-NegativeBacillifromICUpatientsClinicalInfectiousDiseases1996;23:779-85PrevalenceofESBLDatafromIntensiveCareUnit,PekingUnionMedicalCollegeHospital,1999Cross-Resistancein
CAZ-RKlebsiellaDatafromIntensiveCareUnit,PekingUnionMedicalCollegeHospital,1995-1999EffectofESBLonMortalityAnalysisofmortalityin216bacteremicpatientscausedbyKlebsiellapneumoniaePattersonetal.37thICAAC,1997,AbstrJ-210EffectofESBLonMortalityPattersonetal.37thICAAC,1997,AbstrJ-210Empiricantibiotictherapyin32bacteremicpatientscausedbyESBL-positiveKlebsiellapneumoniaeMolecularEpidemiologyofCAZ-RE.ColiandK.PneumoniaeBloodIsolatesSchiappaD,etalRushUniversityandUniversityofIllinois,ChicagoILJournalofinfectiousDiseases1996;174:529-37RiskFactorsforCAZ-R
KlebsiellaBacteremiaCAZ-RKlebsiellaBacteremia*p=0.02OutcomeofPatientswithCAZ-RBacteremiaWhoReceivedAppropriatevs.InappropriateTherapyWithin72HoursofBacteremicEventCeftazidime
--emergenceofresistanceEmergenceofAntibiotic-ResistantPseudomonasaeruginosa:ComparisonofRisksAssociatedwithDifferentAntipseudomonalAgentsbyCarmeliY,etal.AntimicrobialAgentsandChemotherapy1999;43(6):1379-82Ceftazidime
--emergenceofresistancea320-bedurbantertiary-careteachinghospitalinBoston,Mass.11,000admissionsperyear4studyagentswithantipseudomonalactivityceftazidime,ciprofloxacin,imipenem,piperacillinatotalof271patients(followedfor3,810days)withinfectionsduetoP.Aeruginosaweretreatedwiththestudyagentsresistanceemergencein28patients(10.2%),withanincidenceof7.4per1,000patient-daysCeftazidime
--emergenceofresistanceTable.MultivariableCoxhazardmodelsfortheemergenceofresistancetoanyofthefourstudydrugsClassificationofAntibioticTherapyProphylacticUseTherapeuticUseEmpirictherapyDefinitivetherapyEmpiricAntibioticTherapyDepartmentofCriticalCareMedicinePekingUnionMedicalCollegeHospitalEmpiricAntibioticTherapyWhentreatingseriouslyillpatientswhoareatriskofdevelopingsepticshockwhenpathogensareunknownornotconfirmedantibioticselectionaccordingtoepidemiologyofNIinthewardresistancepromostcommonpathogensEmpiricAntibioticTherapySearchingforinfectionfocuscollectingsamplesforculturestartingempiricantibiotictherapyassoonaspossiblereferringtodefinitiveantibiotictherapyassoonaspossibleAntibioticTherapyandPrognosisObjective:ToevaluatetherelationshipbetweentheadequacyofantibiotictreatmentforBSIandclinicaloutcomesamongICUptsDesign:ProspectivecohortstudySetting:AmedicalICU(19beds)andasurgicalICU(18beds)fromauniversity-affiliatedurbanteachinghospitalPatients:492ptsfromJuly1997toJuly1999Intervention:NoneAntibioticTherapyandPrognosis147(29.9%)ptsreceivedinadequateantimicrobialtreatmentfortheirBSIThemostcommonlyidentifiedbloodstreampathogensandtheirassociatedratesofinadequateantimicrobialtreatmentincludedvancomycin-resistantenterococci(n=17;100%)Candidaspecies(n=41;95.1%)MRSA(n=46;32.6%)SCoN(n=96;21.9%)Pseudomonasaeruginosa(n=22;10.0%)
AntibioticTherapyandPrognosisHospitalmortalityrateptswithaBSIreceivinginadequateantimicrobialtx(61.9%)ptswithaBSIreceivingadequateantimicrobialtx(28.4%)(RR,2.18;95%CI,1.77to2.69;p<0.001)Independentdeterminantofhospitalmortalitybymultiplelogisticregressionanalysisadministrationofinadequateantimicrobialtx(OR,6.86;95%CI,5.09to9.24;p<0.001)AntibioticTherapyandPrognosisIndependentpredictoroftheadministrationofinadequateantimicrobialtxbymultiplelogisticregressionanalysisBSIattributedtoCandidaspecies(OR,51.86;95%CI,24.57to109.49;p<0.001)prioradministrationofantibioticsduringthesamehospitalization(OR,2.08;95%CI,1.58to2.74;p=0.008)decreasingserumalbuminconcentrations(1-g/dLdecrements)(OR,1.37;95%CI,1.21to1.56;p=0.014)increasingcentralcatheterduration(1-dayincrements)(OR,1.03;95%CI,1.02to1.04;p=0.008)InappropriateempiricantibiotictherapyObjective:toassesstheincidence,risk,andprognosisfactorsofNPacquiredduringmechanicalventilation(MV)Settingsa1,000-bedteachinghospitalApril1987throughMay
1988Patients78(24%)episodesofNPin322consecutivemechanicallyventilatedpatientsInappropriateempiricantibiotictherapyFrom:Torresetal.Incidence,risk,andprognosisfactorsofnosocomialpneumoniainmechanicallyventilatedpatients.AmRevRespirDis1990Sep;142(3):523-8DifficultyinempiricantibiotictherapyObjective:ToassessthefrequencyofandthereasonsforchangingempiricantibioticsduringthetreatmentofpneumoniaacquiredinICUDesign:Aprospectivemulticenterstudyof1year'sdurationSetting:MedicalandsurgicalICUsin30hospitalsalloverSpain.Patients:Ofatotalof16,872patientsinitiallyenrolledintothestudy,530patientsdeveloped565episodesofpneumoniaafteradmissiontotheICU.DifficultyinempiricantibiotictherapyEmpiricantibioticsin490(86.7%)ofthe565episodesofpneumoniaThemostfrequentlyusedantibioticsamikacin 120casestobramycin 110ceftazidime 96cefotaxime 96Monotherapyin135(27.6%)ofthe490episodesCombinationof2antibioticsin306episodes(62.4%)Combinationof3antibioticsin49episodes(10%)DifficultyinempiricantibiotictherapyTheempirictxmodifiedin214(43.7%)casesisolationofamicroorganismnotcoveredbytreatment 133(62.1%)caseslackofclinicalresponse 77(36%)developmentofresistance 14(6.6%)Individualfactorsassociatedwithmodificationofempirictreatmentidentifiedinthemultivariateanalysismicroorganismnotcovered(RR22.02;95%CI11.54to42.60;p<0.0001)administrationofmorethanoneantibiotic(RR1.29;95%CI1.02to1.65;p=0.021)previoususeofantibiotics(RR1.22;95%CI1.08to1.39;p=0.0018)DifficultyinempiricantibiotictherapyComparedwithappropriateempirictherapy,inappropriatetherapywasassociatedwithhighermortality(p=0.0385)morecomplications(p<0.001)higherincidenceofshock(p<0.005)moreGIB(p=0.003)From:Alvarez-LermaF.Modificationofempiricantibiotictreatmentinpatientswithpneumoniaacquiredintheintensivecareunit.ICU-AcquiredPneumoniaStudyGroup.IntensiveCareMed1996May;22(5):387-94DifficultyinempiricantibiotictherapyObjectiveTodefinetheimpactofBALdataontheselectionofantibioticsandtheoutcomesofpatientswithVAPDesign:ProspectiveobservationandbronchoscopywithBAL,performedwithin24hofdxofanewepisodeofhospital-acquiredVAPorprogressionofapriorepisodeofNPSetting:A15-bedmedicalandsurgicalICUDifficultyinempiricantibiotictherapyPatients:132ptshospitalizedformorethan72hmechanicallyventilatedaneworprogressivelunginfiltrateplusatleasttwoofthefollowingthreeclinicalcriteriaforVAPabnormaltemperature(>38Cor<35C)abnormalWCC(>10,000or<3,000)purulentbronchialsecretionsInterventions:BronchoscopywithBALwithin24hofclinicaldxofVAPorprogressionofaninfiltrateduetopriorVAPorNPAllpatientsreceivedantibiotics,107priortobronchoscopyand25immediatelyafterbronchoscopy.DifficultyinempiricantibiotictherapyFrom:LunaCM,VujacichP,NiedermanMS,VayC,GherardiC,MateraJ,JollyEC.ImpactofBALdataonthetherapyandoutcomeofventilator-associatedpneumonia.Chest1997Mar;111(3):676-85DifficultyinempiricantibiotictherapyFrom:KollefMH,WardSTheinfluenceofmini-BALculturesonpatientoutcomes:implicationsfortheantibioticmanagementofventilator-associatedpneumonia.Chest1998Feb;113(2):412-20HospitalInfectionControlDepartmentofCriticalCareMedicinePekingUnionMedicalCollegeHospitalScheduledChangesofEmpiricAntibioticTherapyObjective:Todeterminetheimpactofascheduledchangeofabxclasses,usedfortheempirictxofsuspectedgram-negativebacterialinfections,ontheincidenceofVAPandnosocomialbacteremiaPatients:680patientsundergoingcardiacsurgerywereevaluatedIntervention:Duringa6-moperiod(i.e.,thebefore-period),ourtraditionalpracticeofprescribinga3rdgenerationcephalosporin(ceftazidime)fortheempirictxofsuspectedgram-negativebacterialinfectionswascontinuedThiswasfollowedbya6-moperiod(i.e.,theafter-period)duringwhichaquinolone(ciprofloxacin)wasusedinplaceofthethird-generationcephalosporin.ScheduledChangesofEmpiricAntibioticTherapyFrom:KollefMH,VlasnikJ,SharplessL,PasqueC,MurphyD,FraserVScheduledchangeofantibioticclasses:astrategytodecreasetheincidenceofventilator-associatedpneumonia.AmJRespirCritCareMed1997Oct;156(4Pt1):1040-8NosocomialInfectionControlScheduledchangesofantibioticclassesforempirictreatmentofsuspectedordocumentedGNBinfectionsTimeperiod1(n=1323) ceftazidime Timeperiod2(n=1243) ciprofloxacin Timeperiod3(n=1102) cefepimeNosocomialInfectionControlScheduledchangesofantibioticclassestargetedattheempirictreatmentofgram-negativebacterialinfectionscanreducetheoccurrenceofinadequateantimicrobialtreatmentofnosocomialinfectionsreducingtheadministrationofinadequateantimicrobialtreatmentforpatientswithanAPACHEII15canimprovehospitalsurvivalFromKollefMH
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 高中数学三角函数图象与性质综合复习教学设计
- 小学三年级综合实践活动教学设计:侦察家庭垃圾的分类与减量实践
- 小学四年级心理健康教育课程我坚持我成功教学设计
- 初中心理健康八年级《人际交往-如果我们换一换》教学设计
- 小学三年级上学期家长会主题班会教案:家校同心话成长携手共育好习惯
- 高中信息技术必修1 教学设计 电子公告板与在线游戏的协同构建与社会化运维
- 小学二年级德育主题班会教学设计《家校同心 护航成长》
- 中小学反诈工作计划
- CN119538342A 基于深度学习的傅里叶变化光谱仪结构设计方法及系统 (山东非金属材料研究所)
- 2026事业单位工勤技能-新疆-新疆假肢制作装配工五级(初级工)历年参考题库含答案详解
- 入额法官责任制度
- 木头下脚料收购协议书
- 贵州国企招聘2025贵州贵阳产业发展控股集团有限公司招聘27人笔试历年参考题库附带答案详解
- 铁路概论课件
- 患者拒绝或放弃医学治疗(或抢救)告知书
- 保险消费者权益保护培训
- DGTJ08-2248-2017 等厚度水泥土搅拌墙技术规程
- 2026届山东省聊城莘县联考化学九年级第一学期期中达标检测试题含解析
- 绒用山羊饲养管理技术
- (高清版)DB11∕T 1557-2025 能效对标实施规范
- GB/T 9237-2017制冷系统及热泵安全与环境要求
评论
0/150
提交评论